BRUIN-CLL-314NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 47 versions: 41 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study sites revised (143)v47
- Minor Site details revised at 1 of 143 sitesv46
- Minor Study sites: 144 to 143v45
- Notable Primary completion pushed from Jun 10, 2025 to Oct 2027
- Enrollment increased: 662 → 737 participants
- Site details revised at 5 of 144 sites
- Minor Site details revised at 5 of 144 sitesv43
Show 35 earlier versionsHide 35 earlier versions
- Minor Site details revised at 5 of 144 sitesv42
- Minor Site details revised at 5 of 144 sitesv41
- Minor Site details revised at 3 of 144 sitesv40
- Minor Site details revised at 12 of 144 sitesv38
- Minor Study sites: 148 to 144v37
- Minor Study sites: 144 to 148v36
- Minor Site details revised at 5 of 144 sitesv35
- Minor Study sites: 148 to 144v34
- Minor Site details revised at 26 of 148 sitesv32
- Minor Site details revised at 9 of 148 sitesv31
- Minor Site details revised at 8 of 148 sitesv30
- Minor Site details revised at 11 of 148 sitesv29
- Minor Site details revised at 1 of 148 sitesv27
- Minor Study sites: 177 to 148v25
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised at 177 of 177 sites
- Minor Enrollment target: estimated 725 to confirmed 662v23
- Minor Primary completion date changed from estimate of Jun 2025 to Jun 10, 2025v22
Notable Eligibility criteria expanded, about 42 wordsv21 Show 5 more changesShow less
- Primary endpoints: 1 to 2
- Enrollment target: 650 to 725
- Secondary endpoints: 6 to 9
- Study arms: 2 to 3
- Collaborators shortened, about 4 words
- Minor Primary completion date: Feb 2025 to Jun 2025
- Study completion date: Aug 2028 to Jan 2028
- Notable Eligibility criteria expanded, about 1 word
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 177 of 177 sites
- Notable Primary completion date: Mar 24, 2028 to Feb 2025
- Study sites: 204 to 177
- Study completion date: Mar 24, 2029 to Aug 2028
- Minor Study sites revised (204)v15
- Minor Study sites: 198 to 204v14
- Minor Study sites: 185 to 198v13
- Notable Eligibility criteria expanded, about 65 words
- Primary endpoint revised
- Study sites: 77 to 185
- Secondary endpoints: 3 to 6
- Minor Study sites: 69 to 77v11
- Minor Study sites: 65 to 69v10
- Minor Study sites: 61 to 65v9
- Minor Study sites: 37 to 61v8
- Minor Study sites: 26 to 37v7
- Minor Study sites: 1 to 26v6
- Minor Collaborators expanded, about 4 wordsv5
- Minor Study sites: 22 to 1v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 22
- Start date changed from estimate of Apr 2022 to Jul 22, 2022
- Minor Study sites: 0 to 1
- Primary completion date: Mar 1, 2028 to Mar 24, 2028
- Study completion date: Mar 1, 2029 to Mar 24, 2029
- Start date: Apr 15, 2022 to Apr 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1
Timeframe: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest] (approximately 3 years and 5 months)
Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2
Timeframe: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest (Approximately 2 years and 3 months)
Secondary (9)
IRC-assessed Progression-Free Survival (PFS)
Investigator assessed Progression-Free Survival (PFS)
Event-Free Survival (EFS)
Duration of Response (DOR)
Overall Survival (OS)
Show 4 moreShow less
Time to Next Treatment (TTNT)
Time to Worsening (TTW) of CLL/SLL Related Symptoms
Comparative Tolerability
Percentage of Participants Achieving DOR Part 2
Arms and interventions
Pirtobrutinib Part 1Experimental
Participants will receive pirtobrutinib orally.
Ibrutinib Part 1Active comparator
Participants will receive ibrutinib orally.
Pirtobrutinib Part 2Experimental
Participants will receive pirtobrutinib orally.
Drugs: Pirtobrutinib, Ibrutinib
Sites
143 sites in 23 countries
United States 19, China 18, Brazil 14, Spain 13, France 10, Poland 8, Turkey (Türkiye) 7, Czechia 6, Italy 6, Chile 4, Germany 4, New Zealand 4, South Korea 4, Taiwan 4, United Kingdom 4, Argentina 3, Australia 3, Canada 3, Belgium 2, Hungary 2, Israel 2, Japan 2, Austria 1